loperamid
antidiarrh
drug
target
receptor
calcium
channel
previou
report
demonstr
loperamid
induc
autophagi
enhanc
antimicrobi
activ
toward
tuberculosi
murin
human
alveolar
macrophag
aim
studi
evalu
immunomodulatori
effect
loperamid
macrophag
respect
cytokin
antimicrobi
peptid
product
mycobacteri
infect
infect
monocytederiv
macrophag
macrophag
tuberculosi
multipl
infect
moi
treat
cell
loperamid
cytokin
product
supernat
cultur
gene
express
cytokin
antimicrobi
peptid
bactericidalperm
increas
protein
bpi
cell
lysat
measur
intracellular
bacteri
load
evalu
enumer
colonyform
unit
day
posttreat
tuberculosi
h
posttreat
smegmati
observ
loperamid
exert
immunomodulatori
effect
product
human
macrophag
infect
tuberculosi
respons
independ
bacteria
also
occur
macrophag
infect
smegmati
lesser
extent
bovi
addit
antibacteri
mechan
trigger
loperamid
induc
signific
reduct
bacteri
load
upregul
bpi
gene
express
thu
result
show
loperamid
exert
immunomodulatori
effect
support
use
addit
medic
condit
diarrhea
previou
studi
demonstr
induct
autophagi
drug
loperamid
could
improv
bactericid
activ
host
cell
may
use
tuberculosi
treatment
adjunct
therapi
loperamid
phenylpiperidin
deriv
commonli
use
treat
infecti
noninfecti
acut
chronic
diarrhea
loperamid
target
two
type
membran
receptor
voltagedepend
voltageindepend
calcium
channel
receptor
loperamid
mediat
intracellular
calcium
level
block
calcium
channel
activ
opioid
receptor
sever
biolog
effect
loperamid
describ
addit
involv
diarrhea
control
suggest
potenti
use
allevi
pain
control
anxieti
reduc
insulin
resist
inhibit
coronaviru
replic
advantag
perform
research
dedic
repurpos
current
avail
drug
includ
consider
reduct
time
cost
requir
discov
new
therapeut
approach
recent
observ
loperamid
enhanc
control
tuberculosi
strain
human
murin
alveolar
macrophag
induc
autophagi
furthermor
antimicrobi
activ
associ
reduct
product
suggest
loperamid
may
play
role
prevent
excess
inflamm
regul
proinflammatori
cytokin
product
desir
tuberculosi
infect
cytokin
type
ii
interferon
despit
protect
role
immun
tuberculosi
induc
hyperinflammatori
state
associ
tissu
damag
tuberculosi
pathogenesi
loperamid
may
induc
addit
immunorespons
associ
effect
calcium
channel
opioid
receptor
blockad
intracellular
calcium
influx
shown
caus
reduct
product
lpsdepend
proinflammatori
cytokin
murin
macrophag
activ
receptor
induc
product
proinflammatori
chemokin
prostaglandin
endotheli
cell
human
peripher
blood
mononuclear
cell
pbmc
thu
loperamid
may
immunomodulatori
activ
could
use
adjunct
therapi
tuberculosi
infect
evalu
elucid
util
new
clinic
indic
studi
goal
assess
abil
loperamid
regul
human
macrophag
respons
infect
virul
strain
tuberculosi
measur
proinflammatori
mediat
profil
induct
two
antimicrobi
peptid
bactericid
permeabl
increas
protein
bpi
cathelicidin
bpi
may
involv
induc
tuberculosi
death
known
downregul
proinflammatori
mediat
product
addit
antimicrobi
peptid
function
observ
loperamid
exert
immunomodulatori
effect
antimicrobi
peptid
product
human
macrophag
infect
tuberculosi
respons
independ
bacteria
also
occur
macrophag
infect
smegmati
lesser
extent
bovi
addit
antibacteri
mechan
trigger
loperamid
includ
upregul
bpi
gene
express
via
receptordepend
immunomodulatori
respons
although
limit
extent
human
diseas
fulli
repres
vitro
model
model
potenti
contribut
earli
identif
priorit
activ
molecul
induc
signal
relev
diseas
biolog
studi
aim
repurpos
exist
drug
monocyt
isol
pbmc
posit
select
use
magnet
bead
miltenyi
biotech
auburn
ca
buffi
coat
sampl
healthi
blood
bank
donor
instituto
nacion
de
enfermedad
respiratoria
ismael
villega
cell
suspens
puriti
viabil
assess
flow
cytometri
reveal
cell
cell
viabil
mean
se
monocyt
suspens
adjust
cellsml
supplement
mm
lglutamin
lonza
walkersvil
md
gentamicin
sulfat
lonza
heatinactiv
human
serum
valley
biomed
winchest
va
cultur
human
monocyt
day
gener
monocytederiv
macrophag
macrophag
time
cell
viabil
observ
assess
trypan
blue
exclus
studi
approv
institut
review
board
instituto
nacion
de
enfermedad
respiratoria
ismael
villega
design
subsequ
vitro
studi
follow
recommend
curti
colleagu
mycobacterium
tuberculosi
tuberculosi
bovi
bcg
smegmati
atcc
manassa
va
cultur
middlebrook
broth
medium
difco
laboratori
detroit
mi
incub
tuberculosi
bovi
bcg
day
smegmati
day
mycobacteri
stock
solut
harvest
aliquot
store
use
colonyform
unit
cfu
enumer
disrupt
mycobacteri
clump
macrophag
macrophageswel
polystyren
plate
infect
tuberculosi
bovi
bcg
smegmati
rpmi
nonheatinactiv
pool
human
ab
serum
without
gentamicin
moi
bacteria
macrophag
cell
incub
h
follow
three
wash
remov
nonphagocytos
bacteria
macrophag
cultur
anoth
hour
rpmi
supplement
heatinactiv
pool
human
serum
without
loperamid
concentr
determin
pilot
assay
cell
cultur
h
collect
supernat
cell
lysat
store
use
supernat
centrifug
use
spinx
tube
mm
membran
corn
new
york
remov
bacteria
macrophag
cell
debri
comparison
purpos
includ
uninfect
cell
treat
loperamid
lp
vehicl
control
evalu
effect
loperamid
mycobacteri
intracellular
growth
control
macrophageswel
polystyren
plate
infect
bacteria
moi
treat
loperamid
extens
wash
remov
nonphagocytos
bacteria
macrophag
infect
tuberculosi
incub
co
atmospher
h
day
h
day
smegmatisinfect
macrophag
cultur
h
loperamid
treatment
set
control
experi
perform
cell
detach
count
determin
number
recov
macrophag
assess
macrophag
viabil
via
trypan
blue
exclus
assay
smegmatisinfect
cell
supernat
discard
cell
lyse
sd
min
neutral
bsa
lysat
serial
dilut
plate
onto
agar
plate
triplic
cfu
tuberculosi
enumer
day
cfu
smegmati
enumer
day
growth
select
experi
naltrexon
ad
min
loperamid
treatment
supernat
h
cultur
assay
releas
gmcsf
use
bioplex
human
cytokin
custom
detect
kit
biorad
hercul
ca
us
follow
manufactur
protocol
select
experi
level
measur
use
inhous
elisa
specif
pair
antibodi
includ
antihuman
pharmingen
san
diego
ca
probiotek
monterrey
mx
previous
describ
supplement
use
neg
control
absorb
read
use
multiskan
ascent
micropl
reader
thermo
fisher
scientif
waltham
nm
result
present
mean
valu
duplic
well
total
rna
extract
revers
transcrib
subsequ
cdna
use
quantit
realtim
pcr
qrtpcr
taqman
assay
determin
mrna
express
level
use
compar
threshold
cycl
method
previous
describ
realtim
pcr
reaction
perform
duplic
well
accord
manufactur
protocol
taqman
predesign
gene
assay
bpi
gene
evalu
gene
assay
purchas
appli
biosystem
carlsbad
ca
ct
valu
gene
normal
endogen
rrna
control
gene
threshold
number
refer
molecul
initi
number
refer
molecul
taken
account
elimin
need
quantifi
initi
amount
cdna
cell
number
method
amount
target
dna
normal
endogen
refer
calcul
rel
calibr
unstimul
select
condit
provid
effici
target
refer
amplif
valid
appli
biosystem
user
bulletin
assess
ligandinduc
respons
macrophag
stimul
use
loperamid
h
block
loperamid
signal
naltrexon
bay
ad
cell
min
loperamid
stimul
next
supernat
collect
frozen
cytokin
assess
cell
harvest
lyse
mrna
extract
cultur
medium
alon
use
neg
control
cell
treat
lp
use
posit
control
indic
use
friedman
anova
follow
dunn
posttest
assess
differ
among
treatment
statist
analys
perform
prism
version
mac
graphpad
softwar
san
diego
ca
p
consid
signific
loperamid
bay
naltrexon
purchas
sigma
aldrich
st
loui
mo
reagent
dissolv
either
dimethyl
sulfoxid
dmso
sigma
aldrich
ethanol
baker
cultur
proport
dmso
ethanol
lower
final
cultur
concentr
reagent
use
report
assay
determin
pilot
assay
macrophag
viabil
assess
use
cell
titer
cell
viabil
assay
promega
madison
wi
usa
signific
reduct
viabil
observ
use
select
concentr
supplementari
fig
previou
report
show
loperamid
enhanc
alveolar
macrophag
antibacteri
respons
tuberculosi
model
addit
immunomodulatori
effect
loperamid
first
demonstr
antibacteri
respons
occur
monocytederiv
macrophag
observ
signific
reduct
intracellular
cfu
macrophag
treat
loperamid
fig
furthermor
loperamid
upregul
express
gene
encod
antimicrobi
peptid
bpi
fig
cathelicidin
fig
next
evalu
abil
loperamid
modul
inflammatori
environ
context
tuberculosi
infect
show
reduc
bacteri
load
observ
infect
macrophag
treat
loperamid
accompani
increas
product
protein
transcript
level
observ
signific
increas
signific
reduct
product
protein
transcript
level
addit
observ
increas
product
gene
express
enzym
respons
synthesi
infect
macrophag
treat
loperamid
addit
lp
infect
macrophag
induc
signific
increas
cytokin
product
compar
nontreat
cell
fig
product
signific
amount
gmcsf
induc
infect
macrophag
compar
nontreat
cell
medium
supplementari
fig
chang
product
signific
treatment
assess
addit
product
modifi
loperamid
lp
treatment
supplementari
fig
control
experi
demonstr
loperamid
alon
affect
macrophag
number
viabil
macrophag
remain
well
viabl
cours
cultur
time
bacteri
infect
reduc
number
cell
viabil
remain
cell
viabl
addit
loperamid
slightli
prevent
cell
loss
remain
cell
viabl
supplementari
fig
observ
regul
inflamm
may
gener
effect
induct
product
loperamid
independ
tuberculosi
infect
evalu
product
upon
treatment
loperamid
alon
observ
loperamid
induc
product
induc
product
signific
amount
macrophag
fig
furthermor
reduct
product
cfu
count
effect
ethanol
use
vehicl
fig
assess
whether
regulatori
effect
loperamid
product
depend
tuberculosi
infect
proinflammatori
respons
stimuli
treat
macrophag
loperamid
stimul
lp
infect
bovi
bcg
smegmati
observ
loperamid
induc
decreas
product
regardless
induc
observ
reduct
signific
cell
infect
smegmati
fig
infect
smegmati
provid
good
model
character
biolog
effect
loperamid
allow
experi
perform
lower
laboratori
biosafeti
level
use
next
sought
determin
whether
effect
loperamid
macrophag
depend
known
receptoractiv
function
loperamid
block
calcium
channel
use
bay
calcium
ionophor
increas
intracellular
calcium
level
treatment
loperamid
addit
loperamid
activ
receptor
use
naltrexon
gener
inhibitor
opioid
receptor
mu
delta
kappa
sigma
prior
treat
smegmatisinfect
macrophag
loperamid
observ
neither
bay
fig
naltrexon
fig
restor
product
level
observ
smegmatisinfect
macrophag
alon
howev
compar
medium
control
product
significantli
augment
macrophag
naltrexon
ad
prevent
activ
receptor
wherea
level
significantli
chang
smegmatisinfect
cell
treat
loperamid
respons
observ
presenc
bay
variabl
bay
level
significantli
higher
background
determin
whether
calcium
channel
opioid
receptor
activ
loperamid
induc
antimicrobi
activ
treat
infect
macrophag
bay
naltrexon
prior
loperamid
stimul
enumer
intracellular
bacteria
observ
significantli
reduc
number
intracellular
bacteria
macrophag
treat
loperamid
fig
concomit
reduct
product
fig
inhibit
opioid
receptor
signal
naltrexon
partial
neutral
effect
loperamid
antimicrobi
activ
restor
product
augment
intracellular
calcium
influx
neutral
effect
loperamid
microbi
kill
product
furthermor
neither
ethanol
etoh
vehicl
loperamid
fig
loperamid
modul
proinflammatori
environ
infect
macrophag
macrophag
infect
tuberculosi
moi
h
extens
wash
cell
treat
loperamid
addit
h
product
measur
cultur
supernat
use
custom
luminex
assay
measur
elisa
left
individu
valu
depict
p
friedman
anova
follow
dunn
multipl
comparison
test
cell
lysat
obtain
assess
gene
express
infect
cell
treat
loperamid
rel
untreat
infect
cell
quantit
pcr
experi
perform
duplic
individu
valu
depict
p
vs
control
dmso
vehicl
bay
naltrexon
modifi
product
antimicrobi
activ
infect
macrophag
observ
partial
contribut
opioid
receptor
antimicrobi
activ
induct
evalu
effect
naltrexon
express
bpi
macrophag
infect
smegmati
fig
b
tuberculosi
fig
observ
loperamidedepend
upregul
bpi
gene
express
macrophag
infect
tuberculosi
neutral
addit
naltrexon
fig
develop
novel
pharmaceut
deter
need
character
drug
pharmacokinet
dose
safeti
inform
human
develop
new
drug
promis
molecul
aim
bring
market
take
ten
year
cost
consider
high
consequ
translat
research
bring
laboratori
find
bedsid
patient
tuberculosi
challeng
therefor
key
strategi
repurpos
current
avail
drug
potenti
use
treat
tuberculosi
previou
report
show
loperamid
abl
stimul
human
murin
macrophag
infect
virul
tuberculosi
strain
elicit
antimicrobi
respons
induc
autophagi
studi
evalu
immunomodulatori
activ
loperamid
context
mycobacteri
infect
observ
loperamid
increas
bactericid
activ
induc
overexpress
antimicrobi
peptid
bpi
macrophag
infect
tuberculosi
antimycobacteri
activ
bpi
report
other
induct
antimicrobi
peptid
relev
tuberculosi
addit
report
express
peptid
decreas
tuberculosi
best
knowledg
fig
loperamid
downregul
product
mycobacteriuminfect
macrophag
cell
stimul
loperamid
ng
ml
lp
h
n
n
product
determin
cultur
supernat
elisa
individu
result
depict
line
indic
median
p
ns
signific
b
cell
infect
tuberculosi
moi
h
extens
wash
cell
treat
loperamid
addit
day
left
h
right
intracellular
bacteri
load
evalu
count
cfu
level
cultur
supernat
determin
elisa
cfu
depict
median
interquartil
rang
boxplot
indic
quartil
median
n
p
vs
medium
etoh
ethyl
alcohol
use
control
c
cell
treat
ng
ml
lp
infect
bovi
bgc
smegmati
moi
h
extens
wash
discard
nonphagocyt
bacteria
cell
treat
loperamid
addit
h
product
determin
cultur
supernat
elisa
box
plot
indic
quartil
median
n
vs
medium
p
select
pair
ns
signific
friedman
anova
follow
dunn
multipl
comparison
test
fig
effect
increas
intracellular
calcium
influx
opioid
receptor
blockad
immunomodul
loperamid
macrophag
infect
smegmati
moi
h
extens
wash
discard
nonphagocyt
bacteria
cell
treat
increas
concentr
bay
b
naltrexon
min
follow
treatment
loperamid
addit
h
product
cultur
supernat
assess
elisa
box
plot
indic
quartil
median
n
vs
medium
p
select
pair
friedman
anova
follow
dunn
multipl
comparison
test
first
studi
report
loperamid
associ
induct
antimicrobi
peptid
bpi
human
cell
although
mechan
associ
loperamidedepend
induct
bpi
product
unknown
macrophag
best
studi
induc
vitamin
induct
vitamin
depend
synthesi
activ
form
oh
enzym
bpi
induc
human
macrophag
sever
pamp
lp
flagellin
bacteri
infect
mechan
involv
bpi
induct
loperamid
may
includ
distinct
signal
transduct
pathway
converg
common
transduct
signal
antimicrobi
peptid
thu
demonstr
addit
antimicrobi
activ
associ
autophagi
induct
loperamid
treatment
induc
antimicrobi
activ
macrophag
infect
tuberculosi
smegmati
associ
antimicrobi
peptid
product
also
observ
loperamid
treatment
induc
reduct
level
increas
product
macrophag
infect
tuberculosi
role
loperamid
regul
inflamm
infect
previous
report
observ
restrict
tuberculosi
infect
activ
also
observ
cell
infect
mycobacteria
smegmati
bovi
exert
suppress
effect
product
induct
loperamid
may
explain
reduct
product
report
partial
act
induc
synthesi
regul
contain
tuberculosi
therefor
induct
product
loperamid
may
particip
mycobacteri
kill
increment
increas
level
addit
antimicrobi
peptid
bpi
modul
host
immun
respons
particip
regul
cytokin
express
target
inflammatori
pathway
tolllik
receptor
nfkb
suggest
induct
bpi
product
loperamid
also
play
role
immunoregul
product
induc
stress
condit
murin
macrophag
observ
display
intermediari
macrophag
phenotyp
character
high
antibacteri
activ
extracellular
trap
induct
character
increas
product
reduc
product
observ
loperamid
induc
product
high
level
gmcsf
bpi
associ
phenotyp
high
level
associ
phenotyp
loperamideinduc
cytokin
antimicrobi
peptid
profil
resembl
intermediari
macrophag
phenotyp
investig
signal
pathway
respons
loperamid
modul
product
use
smegmati
infect
model
induc
higher
amount
tuberculosi
allow
better
discrimin
role
variou
pathway
addit
advantag
fastgrowth
mycobacterium
pretreat
macrophag
calcium
ionophor
bay
restor
inhibit
smegmatisinduc
product
loperamid
suggest
blockad
calcium
channel
loperamid
unlik
respons
observ
modul
product
phenomenon
unexpect
smegmati
inducedproduct
larg
depend
ca
signal
howev
role
calcium
mediat
product
controversi
increas
intracellular
ca
due
calcium
influx
channelmedi
exert
inhibitori
effect
lpsinduc
product
contrast
inhibit
calcium
influx
also
caus
reduc
product
decreas
protect
excess
inflamm
neglig
particip
calcium
blockad
product
antimicrobi
respons
induc
loperamid
observ
mycobacteriuminfect
macrophag
restor
intracellular
calcium
level
bay
prevent
smegmati
kill
phenomenon
unexpect
calcium
channel
blockad
trigger
antimicrobi
autophagi
tuberculosi
report
interfer
macrophag
microbicid
mechan
inhibit
murin
human
macrophag
ca
signal
evad
immun
detect
decreas
phagolysosom
format
macrophag
reactiv
oxygen
speci
product
contribut
intracellular
surviv
tuberculosi
thu
loperamid
like
import
induc
bactericid
mechan
unrel
blockad
ca
influx
loperamid
potent
receptor
agonist
explor
whether
immunomodul
induc
loperamidetr
macrophag
relat
activ
receptor
evalu
effect
naltrexon
opioid
antagonist
effect
neutral
loperamid
gastric
pathway
observ
naltrexon
restor
smegmatisinduc
product
loperamidetr
macrophag
find
suggest
activ
opioid
receptor
loperamid
least
partial
involv
regul
product
addit
observ
activ
opioid
receptor
loperamid
also
mediat
antimicrobi
activ
macrophag
naltrexon
partial
abrog
loperamidedepend
bacteri
clearanc
complet
abrog
upregul
bpi
gene
express
observ
upon
treatment
calcium
ionophor
relationship
opioid
receptor
antimicrobi
peptid
previous
report
possibl
explan
fig
effect
increas
intracellular
calcium
influx
opioid
receptor
blockad
antimicrobi
activ
induc
loperamid
macrophag
infect
smegmati
moi
h
extens
wash
remov
nonphagocyt
bacteria
cell
treat
bay
naltrexon
min
follow
treatment
loperamid
addit
h
intracellular
bacteri
load
evalu
count
cfu
n
p
select
pair
product
determin
cultur
supernat
elisa
b
etoh
dmso
use
control
box
plot
indic
quartil
median
n
p
vs
medium
friedman
anova
follow
dunn
multipl
comparison
test
loperamid
activ
innat
respons
tuberculosismacrophag
beyond
scope
studi
futur
studi
need
ascertain
integr
function
rel
prioriti
conclus
loperamid
induc
receptordepend
immunomodulatori
respons
bactericid
mechan
includ
induct
antimicrobi
peptid
reduct
product
human
macrophag
infect
tuberculosi
smegmati
thu
loperamid
stimul
increas
abil
macrophag
fight
bacteri
infect
protect
tissu
damag
caus
excess
inflamm
result
support
potenti
use
loperamid
treat
infecti
diseas
mycobacteri
infect
addit
find
suggest
agonistdepend
receptor
signal
human
macrophag
potenti
role
immunomodul
infecti
diseas
better
understand
agonistspecif
immunomodulatori
effect
opioid
offer
addit
possibl
select
optim
drug
therapi
confer
favor
andor
less
detriment
side
effect
immun
cell
supplementari
data
articl
found
onlin
http
work
support
consejo
nacion
de
ciencia
grant
funder
role
studi
design
collect
analysi
interpret
data
write
manuscript
decis
submit
manuscript
public
author
declar
conflict
interest
loperamidedepend
bpi
gene
express
regul
receptor
signal
macrophag
infect
smegmati
b
tuberculosi
c
moi
h
extens
wash
discard
nonphagocyt
bacteria
cell
treat
naltrexon
min
follow
treatment
loperamid
addit
h
cell
lysat
obtain
assess
bpi
gene
express
rel
untreat
mycobacteriuminfect
cell
quantit
pcr
experi
perform
duplic
mean
sem
independ
experi
depict
p
vs
control
